• Raw Materials in Biologics Manufacturing Comprehensive Risk Assessment and Classification. Bioprocess International, 23(6), 23–29.

​

• Understanding the Variability in Bioburden Test Results in Biomanufacturing. Pharmaceutical Technology, 20-23.

​

• Investigating Bioreactor Contamination, Modeling Contaminant Introduction, and Ensuring Bioburden Test Reliability. BioPharm International, 38(3), 20-27.

​

• Extractables and Leachable Management Comprehensive Risk Assessment During Process Validation for At-Scale Biopharmaceutical Manufacturing. Bioprocess International, 23(3)E1, 15–20.

​

• Bioreactor Design — Leveraging Established Principles and Modern Insights. Bioprocess International, 23(3)E1, 4–18.

​

• Microbial-Control Hold-Time Assessments: Guidance on Matrix and Bracketing Validation Approaches, 23(3), 23–34.

​

• Buffer and solution mixing-time validation: A risk-assessment framework for analysts using matrix and bracketing approaches. Bioprocess International, 23(1-2), 23–34.

​

• Process Validation: Assessing the Need for At-Scale Physicochemical Stability Studies in Biologics Manufacturing. Bioprocess International, 22(11), E1. 

​

• Maintaining protein disulfide-bond stability during culture harvest: Exploring the effects of temperature and oxygen on reduction-reaction kinetics. Bioprocess International, 22(11), E1.

​

• CPV Monitoring - Optimization of Control Chart Design by Reducing the False Alarm Rate and Nuisance Signal. Science Journal of Applied Mathematics and Statistics.

​

• Strategies Used in Manufacturing Processes to Drive and Control Mammalian Cells to Undergo a Lactate Metabolic Shift. Pharmaceutical Bioprocessing, 12(2),152-157.

​

• Shear Assessment for Cell-Culture Clarification in a Disc-Stack Centrifuge. BIOPROCESS TECHNICAL, 22(3), 2-7.

​

• Characterizing Oxygen Mass Transfer and Shear During Cell Culture Calculating the Maximum Cell Density Supported By a 20,000-Liter Stirred-Tank Bioreactor. Bioprocess International, 22(1-2), 2-10.

​

• Determining Sample Size for Demonstrating Zero Failures Ensuring the Effectiveness of Corrective and Preventive Actions. Bioprocess International, 22(1-2).

​

• CO2 Control Strategy for Large-Scale Cell Culture Bioreactor Operation. Advances in Bioscience and Bioengineering, 12(1), 1-13.

​

• Identifying False Metabolite Measurements During Cell-Culture Monitoring Effective Application of the Multivariate Hotelling’s T2 Statistic. Bioprocess International, 21(11-12), 29-31. 

​

• Validating Prefiltration Dirty-Hold Times for Upstream Media and Feed Solutions Implications for Establishing In-Process Microbial Control. Bioprocess International, 21(9), 26-35.​

​​

• Specification Limits for Biomanufacturing Processes: Comparing Tolerance-Interval and Process-Capability Methods. Bioprocess International, 21(6), 40-43.

​

• Process Validation: Calculating the Necessary Number of Process Performance Qualification Runs. Bioprocess International, 21(5), 37-43.

​

• Quantitative Risk Assessment of Limits for Residual Host-Cell DNA: Ensuring Patient Safety for In Vitro Gene Therapies Produced Using Human-Derived Cell Lines. Bioprocess International, 21(4), 33-37.

​

• Shear-Proof Design Space: Scaling Stirred-Tank Bioreactors for Cell Culture Processes. Bioprocess International, 21(1-2), 36-38.

​​

• Statistical Method for Establishing Control Limits for Nonnormal Data Distribution: Focus on Continued Process Verification Monitoring. Bioprocess International, 20(10), 20-24.